Private biopharmaceutical research, development, and commercialisation company, AiPharma, has announced a strategic alliance with biopharmaceutical company Appili Therapeutics Inc (Appili), to advance the global development of Avigan®/Reeqonus™ (favipiravir).
The UK’s largest laboratory diagnostics company, Randox, has announced a nationwide expansion of ten new adaptive ‘cube’ laboratories across Great Britain, with facilities that provide a rapid and cost-effective model to expand laboratory provision.
MSD and Ridgeback Therapeutics announced that their investigational anti-viral medicine reduced the risk of hospitalisation and death by approximately 50% in non-hospitalised adult patients with mild-to-moderate COVID-19.
The European Patent Office (EPO) has granted a patent to specialist pharmaceutical company, N4 Pharma, for its Nuvec cancer treatment and vaccine delivery system.
The interim results from Aberdeen-born 4D Pharma revealed that the first half of 2021 was a “significant period” for the biotechnology firm, according Proactive.
People with advanced or metastatic urothelial cancer will soon have access to a new treatment option following a NICE recommendation.
Glenmark Pharmaceuticals has announced that it has received marketing approval for its fixed-dose combination nasal spray, Ryaltris, in 13 countries across the UK and EU.
According to a report from the Association of the British Pharmaceutical Industry (ABPI), the UK is taking longer to recover from the COVID-19 pandemic than its European peers.
ViiV Healthcare, global specialist HIV company owned by GlaxoSmithKline (GSK), has announced an exclusive collaboration with Shionogi & Co Ltd (Shionogi) to develop a third-generation HIV integrase inhibitor (INSTI), with potential for ultra-long-acting dosing intervals.
Sanome, an early-stage biotech company based in London and Cambridge, has received support from health and biotech investors from the UK and Europe in its first round of funding.
Informa Pharma Intelligence (IPI) has found that some drug firms may withdraw up to 90% of their products from Northern Ireland, once the Brexit grace period has passed.
Trial will test if radium-223 plus avelumab can improve outcomes for metastatic breast cancer patients
Results showed treatment with Crysvita reduces disease burden for patients
Interim analysis showed significant improvement in radiographic progression-free survival
Research shows that the backlog has been ‘starkest’ in diagnostics
